Medtronic (MDT) Gets FDA Approval for New Pillar Palatal Implant System Labeling

Medtronic, Inc. (NYSE: MDT) announced that the FDA has cleared new labeling information for the Pillar Palatal Implant system which is used to help reduce the severity of snoring in patients. While the Medtronic device had been previously approved for the treatment of snoring and sleep apnea, this latest approval allows ENT surgeons to use up to five Pillar Implants specifically for snoring - good news for patients with wider mouths and softer palate tissue.

This new labeling will allow surgeons to utilize more implants per snoring procedure if it is determined that the patient will have a superior benefit. While FDA has cleared the use of up to five implants for the treatment of snoring, the use of more than three implants for the treatment of mild to moderate obstructive sleep apnea has not yet been studied and is not cleared for use by the FDA.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
• Biogen (BIIB) Receives Positive CHMP Opinion for TOFIDENCE